Novo Nordisk prepares to launch diabetes tablet in India

Rybelsus may be accessible for diabetes patients in India from 2022 onwards, states Novo Nordisk.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk has set its sights on India's large group of diabetes patients as a future market for the treatment Rybelsus, which is the tablet-based form of the Danish pharmaceutical company's newest diabetes treatment semaglutide.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading